CSO-话题@MedSci - williamhill asia

#CSO#

19篇内容 | 1567人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1720657, encodeId=e6a71e20657b2, content=<a href='/topic/show?id=92f8535575' target=_blank style='color:#2F92EE;'>#CSO#</a>, objectTitle=Miracor Medical 宣布 PiCSO® 获得 FDA 试验用器械豁免许可, objectType=article, longId=736789, objectId=ee89e36789b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ee89e36789b7, replyNumber=0, likeNumber=101, createdTime=2023-05-28, rootId=0, userName=mgqwxj, userId=5c6132907836, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ee89e36789b7, moduleTitle=Miracor Medical 宣布 PiCSO® 获得 FDA 试验用器械豁免许可, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=ee89e36789b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720655, encodeId=77001e20655f0, content=<a href='/topic/show?id=92f8535575' target=_blank style='color:#2F92EE;'>#CSO#</a>, objectTitle=【专访】科佰生物CSO邵悦：分子诊断细分市场机遇与挑战, objectType=article, longId=183873, objectId=ce8e1838e35d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce8e1838e35d, replyNumber=0, likeNumber=118, createdTime=2020-07-20, rootId=0, userName=mgqwxj, userId=5c6132907836, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce8e1838e35d, moduleTitle=【专访】科佰生物CSO邵悦：分子诊断细分市场机遇与挑战, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=ce8e1838e35d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720656, encodeId=c05a1e2065665, content=<a href='/topic/show?id=92f8535575' target=_blank style='color:#2F92EE;'>#CSO#</a>, objectTitle=公安部“百城会战”专项行动：为何医药行业CSO公司成打击重点？, objectType=article, longId=185747, objectId=4806185e4732, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4806185e4732, replyNumber=0, likeNumber=83, createdTime=2020-04-02, rootId=0, userName=mgqwxj, userId=5c6132907836, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4806185e4732, moduleTitle=公安部“百城会战”专项行动：为何医药行业CSO公司成打击重点？, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=4806185e4732)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720654, encodeId=1c771e2065464, content=<a href='/topic/show?id=92f8535575' target=_blank style='color:#2F92EE;'>#CSO#</a>, objectTitle=ACSO 2019：免疫治疗在胃癌中新的突破, objectType=article, longId=167888, objectId=b12016e88853, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b12016e88853, replyNumber=0, likeNumber=109, createdTime=2019-11-24, rootId=0, userName=mgqwxj, userId=5c6132907836, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b12016e88853, moduleTitle=ACSO 2019：免疫治疗在胃癌中新的突破, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=b12016e88853)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720650, encodeId=182b1e2065040, content=<a href='/topic/show?id=92f8535575' target=_blank style='color:#2F92EE;'>#CSO#</a>, objectTitle=税务机关撰文揭露两票制下CSO虚开全过程, objectType=article, longId=124294, objectId=54211242941a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=54211242941a, replyNumber=0, likeNumber=84, createdTime=2018-03-12, rootId=0, userName=mgqwxj, userId=5c6132907836, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=54211242941a, moduleTitle=税务机关撰文揭露两票制下CSO虚开全过程, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=54211242941a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720653, encodeId=db951e2065335, content=<a href='/topic/show?id=92f8535575' target=_blank style='color:#2F92EE;'>#CSO#</a>, objectTitle=省政府发通知，鼓励药企搞CSO, objectType=article, longId=137218, objectId=ea7313e21871, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea7313e21871, replyNumber=0, likeNumber=88, createdTime=2019-02-20, rootId=0, userName=mgqwxj, userId=5c6132907836, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea7313e21871, moduleTitle=省政府发通知，鼓励药企搞CSO, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=ea7313e21871)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720652, encodeId=60291e20652f5, content=<a href='/topic/show?id=92f8535575' target=_blank style='color:#2F92EE;'>#CSO#</a>, objectTitle=CSO到底能不能做？, objectType=article, longId=130528, objectId=15fd130528db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=15fd130528db, replyNumber=0, likeNumber=86, createdTime=2018-03-09, rootId=0, userName=mgqwxj, userId=5c6132907836, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=15fd130528db, moduleTitle=CSO到底能不能做？, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=15fd130528db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720646, encodeId=035e1e20646ae, content=<a href='/topic/show?id=92f8535575' target=_blank style='color:#2F92EE;'>#CSO#</a>, objectTitle=CSO性质的公司到底能不能做？, objectType=article, longId=107381, objectId=63f910e38111, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=63f910e38111, replyNumber=0, likeNumber=88, createdTime=2017-08-02, rootId=0, userName=mgqwxj, userId=5c6132907836, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=63f910e38111, moduleTitle=CSO性质的公司到底能不能做？, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=63f910e38111)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720649, encodeId=15621e2064927, content=<a href='/topic/show?id=92f8535575' target=_blank style='color:#2F92EE;'>#CSO#</a>, objectTitle=CSO被罚，药企学术营销转型已是燃眉之急, objectType=article, longId=122627, objectId=3e8b12262efa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3e8b12262efa, replyNumber=0, likeNumber=91, createdTime=2018-07-29, rootId=0, userName=mgqwxj, userId=5c6132907836, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3e8b12262efa, moduleTitle=CSO被罚，药企学术营销转型已是燃眉之急, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=3e8b12262efa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720644, encodeId=43a41e20644a8, content=<a href='/topic/show?id=92f8535575' target=_blank style='color:#2F92EE;'>#CSO#</a>, objectTitle=焦虑：医药CSO转型陷入「合规」困境！, objectType=article, longId=102704, objectId=37da102e04d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=37da102e04d6, replyNumber=0, likeNumber=98, createdTime=2017-09-24, rootId=0, userName=mgqwxj, userId=5c6132907836, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=37da102e04d6, moduleTitle=焦虑：医药CSO转型陷入「合规」困境！, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=37da102e04d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720651, encodeId=41e61e2065171, content=<a href='/topic/show?id=92f8535575' target=_blank style='color:#2F92EE;'>#CSO#</a>, objectTitle=35000家CSO公司倒闭！数据告诉你CSO背后的秘密！, objectType=article, longId=126846, objectId=1ddc1268464d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1ddc1268464d, replyNumber=0, likeNumber=89, createdTime=2018-05-10, rootId=0, userName=mgqwxj, userId=5c6132907836, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1ddc1268464d, moduleTitle=35000家CSO公司倒闭！数据告诉你CSO背后的秘密！, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=1ddc1268464d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720647, encodeId=91d11e2064754, content=<a href='/topic/show?id=92f8535575' target=_blank style='color:#2F92EE;'>#CSO#</a>, objectTitle=只有生产企业才能为医药代表备案，CSO和经销商路在何方？, objectType=article, longId=116338, objectId=769b11633812, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=769b11633812, replyNumber=0, likeNumber=105, createdTime=2017-12-16, rootId=0, userName=mgqwxj, userId=5c6132907836, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=769b11633812, moduleTitle=只有生产企业才能为医药代表备案，CSO和经销商路在何方？, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=769b11633812)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720648, encodeId=717f1e20648fb, content=<a href='/topic/show?id=92f8535575' target=_blank style='color:#2F92EE;'>#CSO#</a>, objectTitle=Free Radic Biol Med：增强骨骼肌中EcSOD表达利于阻止多器官功能障碍综合征的发生, objectType=article, longId=117606, objectId=63b911e6063e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=63b911e6063e, replyNumber=0, likeNumber=124, createdTime=2018-01-30, rootId=0, userName=mgqwxj, userId=5c6132907836, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=63b911e6063e, moduleTitle=Free Radic Biol Med：增强骨骼肌中EcSOD表达利于阻止多器官功能障碍综合征的发生, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=63b911e6063e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720640, encodeId=b5861e20640d5, content=<a href='/topic/show?id=92f8535575' target=_blank style='color:#2F92EE;'>#CSO#</a>, objectTitle=“两票制”改革的思考：渠道商能成功转型CSO吗？, objectType=article, longId=94624, objectId=689294624d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=689294624d4, replyNumber=0, likeNumber=113, createdTime=2018-02-22, rootId=0, userName=mgqwxj, userId=5c6132907836, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=689294624d4, moduleTitle=“两票制”改革的思考：渠道商能成功转型CSO吗？, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=689294624d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720643, encodeId=d2fa1e2064388, content=<a href='/topic/show?id=92f8535575' target=_blank style='color:#2F92EE;'>#CSO#</a>, objectTitle=医药商业为什么不能转型做CSO？, objectType=article, longId=98761, objectId=59d798e61f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=59d798e61f0, replyNumber=0, likeNumber=89, createdTime=2018-01-21, rootId=0, userName=mgqwxj, userId=5c6132907836, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=59d798e61f0, moduleTitle=医药商业为什么不能转型做CSO？, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=59d798e61f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720642, encodeId=8cf51e20642a7, content=<a href='/topic/show?id=92f8535575' target=_blank style='color:#2F92EE;'>#CSO#</a>, objectTitle=关于CSO，这两个认识都是错误的！！！, objectType=article, longId=98434, objectId=d5e99843422, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d5e99843422, replyNumber=0, likeNumber=89, createdTime=2017-05-23, rootId=0, userName=mgqwxj, userId=5c6132907836, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d5e99843422, moduleTitle=关于CSO，这两个认识都是错误的！！！, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=d5e99843422)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720641, encodeId=49391e2064172, content=<a href='/topic/show?id=92f8535575' target=_blank style='color:#2F92EE;'>#CSO#</a>, objectTitle=伪CSO，政策风险越来越大, objectType=article, longId=98144, objectId=0d8098144be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0d8098144be, replyNumber=0, likeNumber=82, createdTime=2017-10-09, rootId=0, userName=mgqwxj, userId=5c6132907836, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0d8098144be, moduleTitle=伪CSO，政策风险越来越大, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=0d8098144be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720645, encodeId=af7c1e2064577, content=<a href='/topic/show?id=92f8535575' target=_blank style='color:#2F92EE;'>#CSO#</a>, objectTitle=药企营销转型的难题：CSO到底能不能做？, objectType=article, longId=103009, objectId=0ba710300941, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0ba710300941, replyNumber=0, likeNumber=86, createdTime=2018-03-16, rootId=0, userName=mgqwxj, userId=5c6132907836, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0ba710300941, moduleTitle=药企营销转型的难题：CSO到底能不能做？, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=0ba710300941)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720639, encodeId=50171e20639e1, content=<a href='/topic/show?id=92f8535575' target=_blank style='color:#2F92EE;'>#CSO#</a>, objectTitle=ACSO乳腺癌威廉亚洲博彩公司更新, objectType=article, longId=48163, objectId=79a8481638c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=79a8481638c, replyNumber=0, likeNumber=109, createdTime=2015-04-25, rootId=0, userName=mgqwxj, userId=5c6132907836, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=79a8481638c, moduleTitle=ACSO乳腺癌威廉亚洲博彩公司更新, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=79a8481638c)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] williamhill asia 话题小助手

CSO

2020-05-29

mgqwxj (审核中...)

前往app查看评论内容

#CSO#

Miracor Medical 宣布 PiCSO® 获得 FDA 试验用器械豁免许可

2023-05-28

mgqwxj (审核中...)

前往app查看评论内容

#CSO#

【专访】科佰生物CSO邵悦：分子诊断细分市场机遇与挑战

2020-07-20

mgqwxj (审核中...)

前往app查看评论内容

#CSO#

公安部“百城会战”专项行动：为何医药行业CSO公司成打击重点？

2020-04-02

mgqwxj (审核中...)

前往app查看评论内容

#CSO#

ACSO 2019：免疫治疗在胃癌中新的突破

2019-11-24

mgqwxj (审核中...)

前往app查看评论内容

#CSO#

税务机关撰文揭露两票制下CSO虚开全过程

2018-03-12

mgqwxj (审核中...)

前往app查看评论内容

#CSO#

省政府发通知，鼓励药企搞CSO

2019-02-20

mgqwxj (审核中...)

前往app查看评论内容

#CSO#

CSO到底能不能做？

2018-03-09

mgqwxj (审核中...)

前往app查看评论内容

#CSO#

CSO性质的公司到底能不能做？

2017-08-02

mgqwxj (审核中...)

前往app查看评论内容

#CSO#

CSO被罚，药企学术营销转型已是燃眉之急

2018-07-29

mgqwxj (审核中...)

前往app查看评论内容

#CSO#

焦虑：医药CSO转型陷入「合规」困境！

2017-09-24

mgqwxj (审核中...)

前往app查看评论内容

#CSO#

35000家CSO公司倒闭！数据告诉你CSO背后的秘密！

2018-05-10

mgqwxj (审核中...)

前往app查看评论内容

#CSO#

只有生产企业才能为医药代表备案，CSO和经销商路在何方？

2017-12-16

mgqwxj (审核中...)

前往app查看评论内容

#CSO#

Free Radic Biol Med：增强骨骼肌中EcSOD表达利于阻止多器官功能障碍综合征的发生

2018-01-30

mgqwxj (审核中...)

前往app查看评论内容

#CSO#

“两票制”改革的思考：渠道商能成功转型CSO吗？

2018-02-22

mgqwxj (审核中...)

前往app查看评论内容

#CSO#

医药商业为什么不能转型做CSO？

2018-01-21

mgqwxj (审核中...)

前往app查看评论内容

#CSO#

关于CSO，这两个认识都是错误的！！！

2017-05-23

mgqwxj (审核中...)

前往app查看评论内容

#CSO#

伪CSO，政策风险越来越大

2017-10-09

mgqwxj (审核中...)

前往app查看评论内容

#CSO#

药企营销转型的难题：CSO到底能不能做？

2018-03-16

mgqwxj (审核中...)

前往app查看评论内容

#CSO#

ACSO乳腺癌威廉亚洲博彩公司更新

2015-04-25

科室
- - 订阅+
  - 更多科室
工具
服务